In a patient with invasive ductal carcinoma of the breast and clinically positive axillary lymph nodes, which surgical procedure is the standard of care for axillary staging?

Explanation

## Axillary Surgical Staging in Clinically Node-Positive Breast Cancer **Key Point:** In clinically node-positive (cN+) breast cancer, axillary lymph node dissection (ALND) of levels I, II, and III is the standard of care for accurate staging and locoregional control. Sentinel lymph node biopsy is NOT appropriate in this setting. ### Indications for ALND vs. SLNB | Clinical Scenario | Recommended Procedure | Rationale | |-------------------|----------------------|----------| | cN0 (clinically node-negative) | SLNB ± completion ALND if sentinel positive | Minimizes morbidity; sentinel node reflects nodal status | | cN+ (clinically node-positive) | ALND levels I, II, III | Comprehensive staging; therapeutic benefit; sentinel mapping unreliable | | cN+ with neoadjuvant therapy → cN0 | SLNB ± ALND based on response | Sentinel mapping may be used post-chemotherapy if cN0 achieved | **High-Yield:** The ACOSOG Z0011 trial (2011) showed that SLNB alone without completion ALND is acceptable in cN0 patients with 1–2 positive sentinel nodes undergoing breast-conserving therapy and systemic therapy. However, this does NOT apply to clinically node-positive patients. ### Levels of Axillary Dissection 1. **Level I (Lateral):** Lymph nodes lateral to the lateral border of pectoralis minor. 2. **Level II (Central):** Lymph nodes between the medial and lateral borders of pectoralis minor. 3. **Level III (Medial/Apical):** Lymph nodes medial to the medial border of pectoralis minor (infraclavicular nodes). **Clinical Pearl:** Complete ALND (levels I, II, III) provides accurate staging (typically 10–40 nodes removed) and therapeutic axillary clearance, reducing axillary recurrence risk from ~20% to <5% in node-positive disease. **Warning:** Omitting ALND in cN+ patients results in understaging, inadequate locoregional control, and increased axillary recurrence risk. SLNB alone is insufficient for nodal burden assessment in this cohort. [cite:NCCN Breast Cancer Guidelines 2023; Veronesi et al., Lancet 2003]